NEW YORK, Oct. 24 - Abbott Laboratories has agreed to acquire Vysis in a stock deal worth about $355 million in an attempt to buttress its position in the DNA-based diagnostic market, the drug giant announced on Wednesday.

Abbott will pay $30.50 per share for Vysis, which is a 33 percent premium on Vysis shares, the company said. Shares in the Downers Grove, Illinois-based company closed at $23 on the Nasdaq on Tuesday.

Vysis manufactures and markets two tests that detect certain genetic markers for breast and bladder cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.